1.39  -0.1 (-6.71%)		06-12 16:00
Open: 1.58 High: 1.58 Volume: 1,065,721		Pre. Close: 1.49 Low: 1.36 Market Cap: 55(M)

Short term
Mid term
Targets	6-month :	2.98	1-year :	3.91
Resists	First :	2.55	Second :	3.34
Pivot price	2.29
Supports	First :	1.25	Second :	1.04
MAs	MA(5) :	1.38	MA(20) :	2.45
	MA(100) :	3.43	MA(250) :	4.91
MACD	MACD :	-0.5	Signal :	-0.3
%K %D	K(14,3) :	7.5	D(3) :	5.6
RSI	RSI(14): 24
52-week	High :	8.58	Low :	1.25

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NYXH ] has closed above bottom band by 19.4%. Bollinger Bands are 229.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.58 - 1.59	1.59 - 1.6
Low:	1.34 - 1.35	1.35 - 1.36
Close:	1.37 - 1.39	1.39 - 1.4

Nyxoah S.A. is a medical technology company dedicated to developing and bringing to market therapies for sleep disordered breathing conditions. Its flagship offering is the Genio system, a CE-Marked, patient-focused hypoglossal neurostimulation therapy that addresses moderate to severe obstructive sleep apnea. Established in 2009, the company maintains its headquarters in Mont-Saint-Guibert, Belgium.

Thu, 11 Jun 2026
Nyxoah Updates Capital Structure After Major Share Issuance - The Globe and Mail

Thu, 11 Jun 2026
Nyxoah (NASDAQ: NYXH) adds 55,232,558 new shares after US offering - Stock Titan

Thu, 11 Jun 2026
Cochlear (NYXH) reports 5.91% beneficial ownership in Nyxoah - Stock Titan

Wed, 10 Jun 2026
After U.S. share sale, Nyxoah nears 100M voting rights - Stock Titan

Wed, 10 Jun 2026
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch - GlobeNewswire

Wed, 10 Jun 2026
Nyxoah raises $95M to expand sleep apnea system in U.S., Europe - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	45 (M)
Shares Float	24 (M)
Held by Insiders	36.1 (%)
Held by Institutions	21.2 (%)
Shares Short	331 (K)
Shares Short P.Month	323 (K)

EPS	-2.49
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.95
Profit Margin	0 %
Operating Margin	-321.8 %
Return on Assets (ttm)	-44.6 %
Return on Equity (ttm)	-130 %
Qtrly Rev. Growth	498.8 %
Gross Profit (p.s.)	0.2
Sales Per Share	0.34
EBITDA (p.s.)	-1.84
Qtrly Earnings Growth	0 %
Operating Cash Flow	-72 (M)
Levered Free Cash Flow	-46 (M)

PE Ratio	-0.57
PEG Ratio	0
Price to Book value	1.44
Price to Sales	4.05
Price to Cash Flow	-0.87

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.